P3 Health Partners (NASDAQ:PIII - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.15), Zacks reports. The firm had revenue of $370.69 million for the quarter, compared to analyst estimates of $378.88 million. P3 Health Partners had a negative net margin of 6.95% and a negative return on equity of 71.31%.
P3 Health Partners Price Performance
Shares of P3 Health Partners stock traded down $0.01 during trading on Monday, reaching $0.16. 340,806 shares of the company's stock were exchanged, compared to its average volume of 976,846. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.53 and a current ratio of 0.53. P3 Health Partners has a 1-year low of $0.15 and a 1-year high of $1.02. The company has a market cap of $58.88 million, a P/E ratio of -0.20 and a beta of 0.94. The firm's 50-day moving average price is $0.19 and its 200 day moving average price is $0.26.
P3 Health Partners Company Profile
(
Get Free Report)
P3 Health Partners Inc, a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc was founded in 2020 and is based in Henderson, Nevada.
See Also
Before you consider P3 Health Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and P3 Health Partners wasn't on the list.
While P3 Health Partners currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
